Q-omics provides the consensus-scored GAPDHP15 profile across patient tissues and cancer cell-line models. GAPDHP15 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GAPDHP15 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, GAPDHP15 RNA expression shows 12,716 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCS, HNSC, and PDAC as cancer lineages where GAPDHP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP15 survival associations across molecular data types. GAPDHP15 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP15 RNA expression–survival associations across cancer types. High GAPDHP15 expression shows unfavorable associations in KICH, LIHC, OV and BLCA, but favorable associations in UCS and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for GAPDHP15 RNA expression.
This table summarizes GAPDHP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP15 shows lower tumor expression in KIRC, BRCA and KICH and higher tumor expression in HNSC and LUAD. The HNSC box plot shows higher GAPDHP15 RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p = .007).
This table shows molecular features associated with GAPDHP15 in patient tissues and cancer cell lines. In patient samples, GAPDHP15 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
